6827results about How to "Inhibitory activity" patented technology

The Data Traffic Controller is a system and method that provides users with the ability to view, control and protect themselves during their online browsing. Most websites come with an array of tracking elements and third-party content which could be unknown or misleading to the user. The Data Traffic Controller interface embraces member functions, events, and properties. The member functions provide high level services such as Proxy, VPN, filter inappropriate content, block or allow certain websites, detect and block trackers, and control browser behavior which includes cookies and history retention. The Data Traffic Controller displays notifications and statistics as it encounters events. It also represents all the tracking and third-party activity and their connectedness using a graph, where the user has the ability to further control individual elements.

A system and method for facilitating the execution of law enforcement duties and enhancing anti-terrorism and counter-terrorism capabilities is disclosed. More particularly, according to one aspect of the invention, an electronic system and associated method is configured to facilitate the performance of law enforcement duties by quasi-instantaneously providing actionable intelligence to its users, such as front-line law enforcement officers, in response to a real-time query. According to another aspect of the invention, a system implements a set of automated status classifications for subjects with suspected or confirmed involvement in criminal and/or terrorist activities. The status classifications specifically and concisely establish the subject's involvement in criminal and/or terrorist activities. According to yet another aspect of the invention, a system executes a streamlined electronic process for asset forfeiture actions so as to ensure that criminal and/or terrorist assets are efficiently and effectively seized.

The invention describes methods of treating depression comprising administering a TNFα antibody, such as a human TNFα antibody. The invention also provides a method for treating depression comprising inhibiting TNFα activity in a subject suffering from depression by systemically administering to the subject a human anti-TNFα antibody, or an antigen-binding portion thereof, such that depression is treated. Also described is a method for the treatment or alleviation of depression or other affective disorders comprising administering an amount of an anti-inflammatory agent effective to treat or alleviate depression or other affective disorder to a subject in need thereof, wherein said anti-inflammatory agent down-regulates peripheral cytokine levels to thereby treat or alleviate depression or other affective disorder.

Methods of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection are disclosed.

Systems, methods, and computer program products for facilitating the reading, transmission and presentation of physiological data within a wireless body area network are disclosed. The remote collection and monitoring of a person's (e.g., patient's) physiological data and activity levels for the purposes of determining the well-being of the person, as well as making additional health status determinations based on the historical information and trends of the collected data are provided. The systems, methods, and computer program products disclosed herein, in varying embodiments, readily lend themselves to incremental component and functionality modifications, which allow for increased sensor data sources, accuracy, reliability and utility of the collected information, further solidifying the uniqueness and desirability of the systems methods and computer program products.

The present invention relates to a compound represented by Formula (I):

and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including solid tumor cancers and hematological cancers.

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from alopecia or acute renal failure or other diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The alopecia may be induced by chemotherapy or radiotherapy, and the patient may be suffering from cancer, in particular breast cancer.

The present invention relates to bioactive ingredients that include isolated bioactive fractions derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant. The bioactive fractions are either free of or substantially free of α-unsaturated γ-lactones (e.g., parthenolide). Further, the bioactive fractions have anti-inflammatory and antioxidant activity. The present invention also relates to a method for isolating a bioactive fraction that is derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant and that is at least substantially free of α-unsaturated γ-lactones (e.g., parthenolide). The present invention also relates to a method for preparing a stabilized cell juice serum fraction and a stabilized concentrated cell juice serum fraction that are free of α-unsaturated γ-lactones (e.g., parthenolide). The present invention also relates to a bioactive composition that includes a mixture of one or more of the isolated bioactive fractions of the present invention.

Methods are provided for treating diseases associated with abnormal activity of kinases. The method comprises: administering a DNA methylation inhibitor to the patient in therapeutically effective amount; and administering a kinase inhibitor to the patient in therapeutically effective amount, such that the in vivo activity of the kinase is reduced relative to that prior to the treatment. The method can be used to treat cancer associated with abnormal activity of kinases such as phosphatidylinositol 3′-kinase (PI3K), protein kinases including serine/threonine kinases such as Raf kinases, protein kinase kinases such as MEK, and tyrosine kinases such as those in the epidermal growth factor receptor family (EGFR), platelet-derived growth factor receptor family (PDGFR), vascular endothelial growth factor receptor (VEGFR) family, nerve growth factor receptor family (NGFR), fibroblast growth factor receptor family (FGFR) insulin receptor family, ephrin receptor family, Met family, Ror family, c-kit family, Src family, Fes family, JAK family, Fak family, Btk family, Syk/ZAP-70 family, and Ab1 family.

Disclosed are medical devices for the prevention and/or treatment of neurological disorders via electrical stimulation, and methods related thereto. The devices may also be utilized to detect disorders before the prevention or treatment of a neurological disorder. These devices are minimally or non-invasive. The present medical devices comprise various components, which include electrodes and control electronics. The electrodes are targeting electrodes constructed from ring type structures or virtually connected disc type arrays. The electrodes are located entirely outside the skull. The present medical devices also comprise one or more subsystems, a control system, a battery unit, and wires connecting the one or more subsystems. These devices may also be used for acute seizure control.

The present invention relates to a novel piperidine derivative represented by formula (1) which shows an inhibitory activity against farnesyl transferase or pharmaceutically acceptable salts thereof, in which A, E and G are defined in the specification; to a process for preparation of the compound of formula (1); to an intermediate which is used in the preparation of the compound of formula (1); and to a pharmaceutical composition comprising the compound of formula (1) as an active ingredient.

Substituted piperidine compounds represented by the structure I are provided,

wherein each of R_1a, R_1b, R_1c, R_1d, R_1e, R_1f, R_1g, R_1h, R₂, R_2A, R₃, R₄, A, X, a, x and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.